Eli Lilly

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Eli Lilly 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About LLY

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. 

CEO
David A. Ricks
CEODavid A. Ricks
Employees
50,000
Employees50,000
Headquarters
Indianapolis, Indiana
HeadquartersIndianapolis, Indiana
Founded
1876
Founded1876
Employees
50,000
Employees50,000

LLY Key Statistics

Market cap
1.03T
Market cap1.03T
Price-Earnings ratio
39.54
Price-Earnings ratio39.54
Dividend yield
0.59%
Dividend yield0.59%
Average volume
3.26M
Average volume3.26M
High today
$1,119.00
High today$1,119.00
Low today
$1,095.23
Low today$1,095.23
Open price
$1,112.24
Open price$1,112.24
Volume
369.96K
Volume369.96K
52 Week high
$1,182.73
52 Week high$1,182.73
52 Week low
$623.78
52 Week low$623.78

Stock Snapshot

With a market cap of 1.03T, Eli Lilly(LLY) trades at $1,097.45. The stock has a price-to-earnings ratio of 39.54 and currently yields dividends of 0.59%.

On 2026-06-22, Eli Lilly(LLY) stock moved within a range of $1,095.23 to $1,119.00. With shares now at $1,097.45, the stock is trading +0.2% above its intraday low and -1.9% below the session's peak.

Trading activity shows a volume of 369.96K, compared to an average daily volume of 3.26M.

Over the past 52 weeks, Eli Lilly(LLY) stock has traded between a high of $1,182.73 and a low of $623.78.

Over the past 52 weeks, Eli Lilly(LLY) stock has traded between a high of $1,182.73 and a low of $623.78.

LLY News

Investing.com 1h
Cantor Fitzgerald reiterates Eli Lilly stock Overweight rating at $1,230 - Investing.com

...

Cantor Fitzgerald reiterates Eli Lilly stock Overweight rating at $1,230 - Investing.com
TipRanks 5h
Eli Lilly, BioArctic enter research pact for BrainTransporter combination

BioArctic announced that the company has entered into a research and collaboration agreement with Eli Lilly (LLY) regarding a potential new treatment combining...

Simply Wall St 6h
Eli Lilly Teams Up With BioArctic On A New Neurodegeneration Therapy

Eli Lilly (NYSE:LLY) announced a new research and collaboration agreement with BioArctic AB to develop a neurodegeneration therapy using BioArctic's BrainTransp...

Eli Lilly Teams Up With BioArctic On A New Neurodegeneration Therapy

Analyst ratings

84%

of 32 ratings
Buy
84.4%
Hold
9.4%
Sell
6.3%

More LLY News

24/7 Wall St. 18h
The 2 Factors That Will Decide Whether XLV Finally Catches the S&P 500 in 2026

The 2 Factors That Will Decide Whether XLV Finally Catches the S&P 500 in 2026 By Marc Guberti Published Jun 21, 4:17PM EDT Quick Read XLV sits at $149, down...

The 2 Factors That Will Decide Whether XLV Finally Catches the S&P 500 in 2026
Nasdaq 2d
Pfizer's Dividend Yield is 10X Bigger Than Eli Lilly's. Does That Make It the Better Stock for Income Investors?

Key Points Eli Lilly is a market darling because it is a leader in the GLP-1 weight-loss market. Pfizer hasn't even entered the GLP-1 race yet, which is one r...

Pfizer's Dividend Yield is 10X Bigger Than Eli Lilly's. Does That Make It the Better Stock for Income Investors?
Nasdaq 2d
Lilly's 7 Acquisitions in 3 Months: Which Will Be the Biggest Game-Changer for the Pharma Giant?

Key Points Eli Lilly has been buying up many small biotechs recently as it navigates its next steps. The latest deals could open up opportunities for new ther...

Lilly's 7 Acquisitions in 3 Months: Which Will Be the Biggest Game-Changer for the Pharma Giant?
Nasdaq 2d
Vertex Has a Head Start in Non-Opioid Pain. Eli Lilly Just Spent Billions to Catch Up. Here's What That Means for Both Stocks.

Key Points Vertex Pharmaceuticals and Eli Lilly are both going after the non-opioid pain management market. Vertex Pharmaceuticals has a lead, but both drugma...

Vertex Has a Head Start in Non-Opioid Pain. Eli Lilly Just Spent Billions to Catch Up. Here's What That Means for Both Stocks.
Nasdaq 3d
The Next Wave of Medical AI Could Mint More Millionaires Than the First -- Here Are the Stocks to Own

Key Points Drugmakers and lab platforms putting AI tools to work in real-world drug development. Eli Lilly is using AI partnerships and financial momentum to...

The Next Wave of Medical AI Could Mint More Millionaires Than the First -- Here Are the Stocks to Own
Simply Wall St 4d
Eli Lilly Expands TuneLab As It Builds Pain And Cancer Pipeline

Eli Lilly (NYSE:LLY) is expanding its TuneLab AI drug discovery platform through new collaborations with Charles River Laboratories and Chai Discovery. The com...

Eli Lilly Expands TuneLab As It Builds Pain And Cancer Pipeline
TipRanks 4d
Lilly’s Lepodisiran Trial Targets Lp(a) as a New Front in Heart Risk

Eli Lilly And Company (LLY) announced an update on their ongoing clinical study. Unlock powerful investing tools and data-driven insights with TipRanks Premium...

People also own

Based on the portfolios of people who own LLY. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.